9 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 22
Current report (foreign)
6:28am
continues to innovate and deliver for patients with life-threatening conditions. Oncology, with 225.3 billion yen in reported revenue, declined -12
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
17 Dec 20
Current report (foreign)
6:01am
possible science, internally or externally, and invest for the long term. Takeda R&D is modality agnostic, and we innovate through a strong internal … growth. These programs leverage new platform capabilities in cell therapy, gene therapy and data sciences. We innovate along the asset life cycles — from
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 May 23
Current report (foreign)
6:19am
to sales, profit and margin growth in the near-term. We will continue to invest in R&D and data and technology to innovate and secure long- term
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 21
Current report (foreign)
6:04am
a wider audience. Stay tuned for future updates on our anniversary activities and how we are continuing to innovate. Shooting the TV commercial Members
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 Jun 21
Current report (foreign)
7:38am
speed of innovation, and we will continue to innovate sustainably and responsibly to increase our R&D output. The innovation level of our new … and scientists, internally and externally, and invest for the long term. Our R&D is modality agnostic. We innovate through a strong internal laboratory
6-K
EX-99.1
yjac3pv1 tzosv8k9
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
- Prev
- 1
- Next